

THIRD EDITION

Hematopoietic Stem Cell Transplantation:

A Manual for Nursing Practice

Edited by

Kim Schmit-Pokorny, RN, MSN, OCN[®], BMTCN[®], and
Seth Eisenberg, RN, ADN, OCN[®], BMTCN[®]

Oncology Nursing Society
Pittsburgh, Pennsylvania

ONS Publications Department

Publisher and Director of Publications: William A. Tony, BA, CQIA
Senior Editorial Manager: Lisa M. George, BA
Assistant Editorial Manager: Amy Nicoletti, BA, JD
Acquisitions Editor: John Zaphyr, BA, MEd
Staff Editor: Andrew Petyak, BA
Associate Staff Editor: Casey S. Kennedy, BA
Design and Production Administrator: Dany Sjoen
Editorial Assistant: Judy Holmes

Copyright © 2020 by the Oncology Nursing Society. All rights reserved. No part of the material protected by this copyright may be reproduced or utilized in any form, electronic or mechanical, including photocopying, recording, or by an information storage and retrieval system, without written permission from the copyright owner. For information, visit www.ons.org/publications-journals/permissions-archives, or send an email to pubpermissions@ons.org.

Library of Congress Cataloging-in-Publication Data

Names: Schmit-Pokorny, Kim, editor. | Eisenberg, Seth, editor. | Oncology Nursing Society, issuing body.

Title: Hematopoietic stem cell transplantation : a manual for nursing practice / edited by Kim Schmit-Pokorny, Seth Eisenberg.

Other titles: Hematopoietic stem cell transplantation (Ezzone)

Description: Third edition. | Pittsburgh, Pennsylvania : Oncology Nursing Society, [2020] | Includes bibliographical references and index.

Identifiers: LCCN 2020007411 (print) | LCCN 2020007412 (ebook) | ISBN 9781635930405 (paperback) | ISBN 9781635930412 (ebook)

Subjects: MESH: Hematopoietic Stem Cell Transplantation--nursing

Classification: LCC RD123.5 (print) | LCC RD123.5 (ebook) | NLM WH 380 | DDC 616.02/774--dc23

LC record available at <https://lccn.loc.gov/2020007411>

LC ebook record available at <https://lccn.loc.gov/2020007412>

Publisher's Note

This book is published by the Oncology Nursing Society (ONS). ONS neither represents nor guarantees that the practices described herein will, if followed, ensure safe and effective patient care. The recommendations contained in this book reflect ONS's judgment regarding the state of general knowledge and practice in the field as of the date of publication. The recommendations may not be appropriate for use in all circumstances. Those who use this book should make their own determinations regarding specific safe and appropriate patient care practices, taking into account the personnel, equipment, and practices available at the hospital or other facility at which they are located. The editors and publisher cannot be held responsible for any liability incurred as a consequence from the use or application of any of the contents of this book. Figures and tables are used as examples only. They are not meant to be all-inclusive, nor do they represent endorsement of any particular institution by ONS. Mention of specific products and opinions related to those products do not indicate or imply endorsement by ONS. Websites mentioned are provided for information only; the hosts are responsible for their own content and availability. Unless otherwise indicated, dollar amounts reflect U.S. dollars.

ONS publications are originally published in English. Publishers wishing to translate ONS publications must contact ONS about licensing arrangements. ONS publications cannot be translated without obtaining written permission from ONS. (Individual tables and figures that are reprinted or adapted require additional permission from the original source.) Because translations from English may not always be accurate or precise, ONS disclaims any responsibility for inaccuracies in words or meaning that may occur as a result of the translation. Readers relying on precise information should check the original English version.

Printed in the United States of America



Innovation • Excellence • Advocacy

We dedicate this book to our patients and their families. We thank the authors of each chapter for their expertise and contributions to complete the third edition of *Hematopoietic Stem Cell Transplantation: A Manual for Nursing Practice*. We also appreciate the thoughtful comments from the field reviewers.

I thank my husband, Kevin, and children, Christopher and Megan, for their love and encouragement that supported me throughout this project. I also thank my colleagues at my work and across the country for their support and the work that they do for our patients.

—Kim Schmit-Pokorny

In addition, I thank Rosemary Ford for her unwavering passion for hematopoietic stem cell transplantation nursing practice and education, as well as for her invaluable guidance and mentorship.

—Seth Eisenberg

Contributors

Editors

Kim Schmit-Pokorny, RN, MSN, OCN®, BMTCN®

Manager, Blood and Marrow Transplant Program
Nebraska Medicine
Omaha, Nebraska
Chapter 5. Stem Cell Collection

Seth Eisenberg, RN, ADN, OCN®, BMTCN®

Professional Practice Coordinator, Infusion Services
Seattle Cancer Care Alliance
Seattle, Washington
Chapter 10. Hepatorenal and Bladder Complications

Authors

Jody B. Acheson, RN, DNP, MPH, OCN®, BMTCN®

Bone Marrow Transplant/Hematologic Malignancies Program Manager
St. Luke's Cancer Institute
Boise, Idaho
Chapter 4. Considerations in Program Development and Sites of Care

Shelley Burcat, MSN, RN, AOCNS®, CCCTM

Clinical Nurse Specialist
Philadelphia, Pennsylvania
Chapter 3. Current Research

Katherine Byar, MSN, APN, BC, BMTCN®

Nurse Practitioner
Nebraska Medicine
Omaha, Nebraska
Chapter 6. Transplant Treatment Course and Acute Complications

Suni Dawn Elgar, MPH, BSN, RN, OCN®

Associate Director of Clinical Operations, Apheresis, Blood and Marrow Transplant, Hematology, and Immunotherapy
Seattle Cancer Care Alliance
Seattle, Washington
Chapter 13. Relapse and Subsequent Malignancies

Kelly A. Hofstra, RN, BSN, OCN®, BMTCN®

Program Coordinator
St. Luke's Cancer Institute
Boise, Idaho
Chapter 4. Considerations in Program Development and Sites of Care

Keriann Kordas, MSN, APN

Advanced Practice Provider, Hematology/Oncology, Cellular Therapy
University of Chicago Medicine
Chicago, Illinois
Chapter 12. Neurologic Complications

Martha Lassiter, RN, MSN, AOCNS®, BMTCN®

Clinical Nurse Specialist
Division of Cellular Therapy and Hematologic Malignancies
Duke University Health System
Durham, North Carolina
Chapter 1. Overview of Hematopoiesis and Immunology

Theresa Latchford, RN, MS, BMTCN®, AOCNS®

Oncology Clinical Nurse Specialist
Stanford Health Care
Stanford, California
Chapter 16. Emerging Cellular Therapies: Chimeric Antigen Receptor T Cells

Rebecca Martin, BSN, RN, OCN®, BMTCN®

Staff Registered Nurse/Educator
Froedtert Hospital, Medical College of Wisconsin
Milwaukee, Wisconsin
Chapter 9. Gastrointestinal Complications

Sandra A. Mitchell, PhD, CRNP, AOCN®

Research Scientist, Outcomes Research Branch
Nurse Practitioner, Chronic Graft-Versus-Host Disease Clinic and Study Group
National Cancer Institute
Rockville, Maryland
Chapter 7. Acute and Chronic Graft-Versus-Host Disease

Joyce L. Neumann, PhD, APRN, AOCN®, BMTCN®

Program Director, Stem Cell Transplantation and Cellular Therapy
Adjuvant Ethicist, Section of Integrated Ethics
University of Texas MD Anderson Cancer Center
Houston, Texas
Chapter 15. Ethical Considerations

Kimberly A. Noonan, DNP, ANP-BC, AOCN®

Nurse Practitioner
Dana-Farber Cancer Institute
Boston, Massachusetts
Chapter 9. Gastrointestinal Complications

Rebecca Pape, MSN, APN, FNP-C

Advanced Practice Provider, Hematology/Oncology, Cellular Therapy
University of Chicago Medicine
Chicago, Illinois
Chapter 12. Neurologic Complications

Pamela D. Papham, DNP, AOCNP®, FNP-BC, FAANP

Nurse Practitioner (BMT Survivorship)
Roswell Park Comprehensive Cancer Center
Buffalo, New York
Assistant Dean of MS/DNP Programs
Clinical Professor of Nursing
State University of New York at Buffalo
Buffalo, New York
Chapter 7. Acute and Chronic Graft-Versus-Host Disease

Lisa A. Pinner, RN, MSN, CNS, CPON®, BMTCN®

Clinical Nurse Specialist
Stanford Children's Hospital
Palo Alto, California
Chapter 14. Late Effects and Survivorship Care

Jean A. Ridgeway, DNP, MSN, APN, AOCN®

Advanced Practice Provider, Hematology/Oncology, Cellular Therapy
University of Chicago Medicine
Chicago, Illinois
Chapter 12. Neurologic Complications

Robin Rosselet, DNP, APRN-CNP, AOCN®

Director of Oncology Advanced Practice Providers
Assistant Professor, The Ohio State University College of Nursing
Arthur G. James Cancer Hospital and Solove Research Institute at
The Ohio State University
Columbus, Ohio
Chapter 8. Hematologic Effects

Elaine Z. Stenstrup, MSN, APRN, ACNS-BC, AOCNS®, BMTCN®

Clinical Nurse Specialist, Oncology and Blood and Marrow Transplant
University of Minnesota Health
Minneapolis, Minnesota
Chapter 2. Basic Concepts of Transplantation

Jennifer M.L. Stephens, MA, PhD, RN, OCN®

Assistant Professor
Athabasca University
Athabasca, Alberta, Canada
Staff Nurse
Leukemia/Bone Marrow Transplant Program of British Columbia
Vancouver General Hospital
Vancouver, British Columbia, Canada
Chapter 11. Cardiopulmonary Complications

Kelli Thoele, PhD, RN, ACNS-BC, BMTCN®, OCN®

Clinical Nurse Specialist
Robert Wood Johnson Future of Nursing Scholar
Indiana University School of Nursing
Indianapolis, Indiana
Chapter 17. Professional Practice

D. Kathryn Tierney, RN, BMTCN®, PhD

Oncology Clinical Nurse Specialist
Blood and Marrow Transplantation
Stanford Health Care
Stanford, California
Clinical Assistant Professor, Division of Primary Care and Population
Health
Stanford University School of Medicine
Stanford, California
Chapter 14. Late Effects and Survivorship Care; Chapter 16. Emerging Cellular Therapies: Chimeric Antigen Receptor T Cells

Mihkaila Maurine Wickline, MN, RN, AOCN®, BMTCN®

Nursing Supervisor, Long-Term Follow-Up
Seattle Cancer Care Alliance
Seattle, Washington
Chapter 13. Relapse and Subsequent Malignancies

Disclosures

Editors and authors of books and guidelines provided by the Oncology Nursing Society are expected to disclose to the readers any significant financial interest or other relationships with the manufacturer(s) of any commercial products.

A vested interest may be considered to exist if a contributor is affiliated with or has a financial interest in commercial organizations that may have a direct or indirect interest in the subject matter. A “financial interest” may include, but is not limited to, being a shareholder in the organization; being an employee of the commercial organization; serving on an organization’s speakers bureau; or receiving research funding from the organization. An “affiliation” may be holding a position on an advisory board or some other role of benefit to the commercial organization. Vested interest statements appear in the front matter for each publication.

Contributors are expected to disclose any unlabeled or investigational use of products discussed in their content. This information is acknowledged solely for the information of the readers.

The contributors provided the following disclosure and vested interest information:

Kim Schmit-Pokorny, RN, MSN, OCN®, BMTCN®: Juno Therapeutics, Kite Pharma, Novartis, consultant or advisory role, honoraria

Seth Eisenberg, RN, ADN, OCN®, BMTCN®: B. Braun Medical, Genentech, ICU Medical, United States Pharmacopeia, consultant or advisory role; ICU Medical, honoraria

Katherine Byar, MSN, APN, BC, BMTCN®: Creative Educational Concepts, honoraria

Keriann Kordas, MSN, APN: Kite Pharma, consultant or advisory role; Merck, honoraria

Theresa Latchford, RN, MS, BMTCN®, AOCNS®: Kite Pharma, honoraria

Rebecca Martin, BSN, RN, OCN®, BMTCN®: Jazz Pharmaceuticals, honoraria

Kimberly A. Noonan, DNP, ANP-BC, AOCN®: Celgene, consultant or advisory role

Pamela D. Paplham, DNP, AOCNP®, FNP-BC, FAANP: American Society for Transplantation and Cellular Therapy, honoraria

D. Kathryn Tierney, RN, BMTCN®, PhD: American Society for Transplantation and Cellular Therapy, Oncology Nursing Society, honoraria

Licensing Opportunities

The Oncology Nursing Society (ONS) produces some of the most highly respected educational resources in the field of oncology nursing, including ONS's award-winning journals, books, online courses, evidence-based resources, core competencies, videos, and information available on the ONS website at www.ons.org. ONS welcomes opportunities to license reuse of these intellectual properties to other organizations.

Licensing opportunities include the following:

- **Reprints**—Purchase high-quality reprints of ONS journal articles, book chapters, and other content directly from ONS, or obtain permission to produce your own reprints.
- **Translations**—Translate and then resell or share ONS resources internationally.
- **Integration**—Purchase a license to incorporate ONS's oncology-specific telephone triage protocols or other resources into your institution's EMR or EHR system.
- **Cobranding**—Display your company's logo on ONS resources for distribution to your organization's employees or customers.
- **Educational reuse**—Supplement your staff or student educational programs using ONS resources.
- **Customization**—Customize ONS intellectual property for inclusion in your own products or services.
- **Bulk purchases**—Buy ONS books and online courses in high quantities to receive great savings compared to regular pricing.

As you read through the pages of this book, think about whether any of these opportunities are the right fit for you as you consider reusing ONS content—and the contents of this book—for your organization.

Contact licensing@ons.org with your licensing questions or requests.

Contents

PREFACE	xi	Caregiver Support	76
		Professional Transplant Community	77
		Quality Management	77
		Accreditation, Regulation, and the Quality Plan	77
		Outcomes: Data, Reporting, and the Stem Cell Therapeutic Outcomes Database.....	79
		Summary	79
		References	79
CHAPTER 1. OVERVIEW OF HEMATOPOIESIS AND IMMUNOLOGY	1	CHAPTER 5. STEM CELL COLLECTION	85
Introduction.....	1	Introduction.....	85
Hematopoiesis and Immunology Across the Life Span	1	Evaluation of Autologous and Allogeneic Donors for Collection.....	85
Hematopoietic Structure and Function	2	Bone Marrow Harvest.....	85
Immune Function: Cells and Responses.....	5	Peripheral Blood Stem Cell Collection.....	89
Organs of the Immune System.....	7	Mobilization of Stem Cells	90
Summary	9	Apheresis Issues.....	96
References	9	Allogeneic Blood Stem Cell Collection	99
		Unrelated Blood Stem Cell Collection.....	101
CHAPTER 2. BASIC CONCEPTS OF TRANSPLANTATION	13	Mismatched and Haploidentical Donors.....	101
Introduction.....	13	Pediatric Blood Stem Cell Collection	102
Types of Hematopoietic Stem Cell Transplants	14	Psychological and Ethical Issues Related to Stem Cell Donation ...	102
Nonmyeloablative Hematopoietic Stem Cell Transplantation	15	Cord Blood Stem Cell Transplantation.....	103
Sources of Stem Cells	15	Stem Cell Processing	105
Be The Match (National Marrow Donor Program)	17	Stem Cell Manipulation.....	105
Preparative Regimens	17	Future Directions	105
Clinical Evaluation	18	Summary	106
Patient and Family Education	19	References	106
Summary	21		
References	21	CHAPTER 6. TRANSPLANT TREATMENT COURSE AND ACUTE COMPLICATIONS	111
		Introduction.....	111
CHAPTER 3. CURRENT RESEARCH	23	Conditioning Regimens for Hematopoietic Stem Cell Transplantation	111
Introduction.....	23	Cellular Infusion of Hematopoietic Stem Cells.....	119
Clinical Trials	23	After Stem Cell Infusion.....	121
Scientific Review Committee	23	Engraftment Phase.....	128
Institutional Review Board	24	Patient and Caregiver Education	130
National Cancer Institute National Clinical Trials Network.....	25	Summary	130
Resources for Clinical Investigation in Blood and Marrow Transplantation	26	References	131
Nursing Research.....	30		
Gene Therapy.....	32	CHAPTER 7. ACUTE AND CHRONIC GRAFT-VERSUS-HOST DISEASE	133
Nonmalignant Diseases Treated With Hematopoietic Stem Cell Transplantation	44	Introduction.....	133
Summary	54	Definitions.....	133
References	54	Acute Graft-Versus-Host Disease.....	134
		Chronic Graft-Versus-Host Disease	141
CHAPTER 4. CONSIDERATIONS IN PROGRAM DEVELOPMENT AND SITES OF CARE	63	Preventing and Treating Acute and Chronic Graft-Versus-Host Disease	148
Introduction.....	63	Strategies for Prophylaxis and Treatment	161
Initial Program Development	63	Components of Supportive Care	164
Care Continuum	64		
Interprofessional Team	67		
Nurse Leadership.....	72		
Transplant Nurses and Professional Development.....	74		
Resource Utilization.....	75		

Preclinical and Developmental Strategies for Prophylaxis, Treatment, and Control.....	171
Induction of Graft-Versus-Host Disease: Preserving the Graft-Versus-Tumor Effect	174
Summary	175
References	175

CHAPTER 8. HEMATOLOGIC EFFECTS 185

Introduction.....	185
Neutropenia.....	185
Thrombocytopenia.....	192
Anemia	195
Blood Product Transfusions.....	198
Delayed Engraftment.....	199
Late Post-Transplant Infections (More Than 100 Days).....	199
Summary	200
References	200

CHAPTER 9. GASTROINTESTINAL COMPLICATIONS 203

Introduction.....	203
Mucositis.....	203
Salivary Gland Dysfunction and Xerostomia	208
Taste Changes.....	209
Nutrition	209
Nausea and Vomiting	211
Diarrhea.....	214
Summary	216
References	217

CHAPTER 10. HEPATORENAL AND BLADDER COMPLICATIONS 221

Introduction.....	221
Hepatic Sinusoidal Obstruction Syndrome	221
Hepatitis.....	229
Kidney Injury.....	231
Transplant-Associated Thrombotic Microangiopathy	237
Hemorrhagic Cystitis	238
Summary	241
References	241

CHAPTER 11. CARDIOPULMONARY COMPLICATIONS 247

Introduction.....	247
Pulmonary Complications.....	247
Nursing Care of Pulmonary Complications	265
Cardiac Complications.....	266
Nursing Care of Cardiac Complications	271
Summary	271
References	271

CHAPTER 12. NEUROLOGIC COMPLICATIONS 283

Introduction.....	283
Neurotoxicities of Common Agents	284
Neurotoxicities of Infectious Diseases.....	286
Other Causes of Neurologic Complications.....	290
Neurocognitive Dysfunction.....	293
Long-Term Neurotoxicities	294
Summary	296
References	296

CHAPTER 13. RELAPSE AND SUBSEQUENT MALIGNANCIES 301

Introduction.....	301
-------------------	-----

Relapse After Hematopoietic Stem Cell Transplantation.....	301
Subsequent Malignancies After Hematopoietic Stem Cell Transplantation	306
Summary	310
References	311

CHAPTER 14. LATE EFFECTS AND SURVIVORSHIP CARE 315

Introduction.....	315
Survivorship Care.....	315
Late Infectious Complications.....	316
Vaccinations	323
Organ-Specific Toxicities	323
Relapse and Subsequent Malignancies	329
Health-Related Quality of Life	329
Caregivers	329
Summary	330
References	330

CHAPTER 15. ETHICAL CONSIDERATIONS 337

Introduction.....	337
Transplantation as a Treatment Option: Beneficence and Nonmaleficence.....	337
Informed Consent: Autonomous Decision	339
Patient Education: Preparing for Treatment Outcomes	340
Donor Issues	341
Outcomes of Disease and Treatment: Undesirable Consequences	341
Summary	345
References	345

CHAPTER 16. EMERGING CELLULAR THERAPIES: CHIMERIC ANTIGEN RECEPTOR T CELLS 349

Introduction.....	349
Overview of the Immune System and Immunotherapy	349
Building a Chimeric Antigen Receptor T Cell	350
Mechanism of Action	350
Pivotal Trials	351
U.S. Food and Drug Administration Approval.....	354
Five Steps to Chimeric Antigen Receptor T-Cell Therapy	355
Toxicities and Side Effects of Chimeric Antigen Receptor T-Cell Therapy	356
Building an Immunotherapy Program: Teams and Infrastructure	364
Summary	366
References	366

CHAPTER 17. PROFESSIONAL PRACTICE 369

Introduction.....	369
Professional Regulation.....	369
Hematopoietic Stem Cell Transplantation Nursing Specialty.....	370
Education.....	370
Self-Care	371
Advocacy.....	372
Communication.....	373
Interprofessional Collaboration.....	375
Leadership.....	377
Professional Practice Evaluation	379
Evidence-Based Practice	379
Research	381
Summary	383
References	384

INDEX 389

Preface

Hematopoietic stem cell transplantation (HSCT) has evolved into a treatment option for many types of diseases, and indications for HSCT continue to expand. The term *HSCT* will be used to identify transplantation throughout the book. The reader must read carefully to determine if the source of stem cells is autologous, syngeneic, or allogeneic; if the stem cells are collected from the bone marrow, peripheral blood, or umbilical cord blood; and if the preparative regimen is myeloablative or nonmyeloablative.

This publication was preceded by nursing manuals related to bone marrow (1994) and peripheral blood stem cell transplantation (1997) that were published by the Oncology Nursing Society (ONS). Many institutions used these books as guidelines for nursing practice and education. For many years, HSCT was seen as highly experimental treatment as pioneers in the field sought to improve outcomes and look for innovative ways to mitigate side effects. As a result of this research, standards have emerged for medicine and nursing practice, which ultimately paved the way for certification.

The first and second editions of *Hematopoietic Stem Cell Transplantation: A Manual for Nursing Practice* were published by ONS in 2004 and 2013, respectively. We thank the previous editor, Susan Ezzone, for her work as editor on both editions. In this edition, we want to continue to promote the expansion and dissemination of knowledge regarding HSCT for nurses working in the specialty and nurses caring for patients prior to and after transplantation. The specialty of HSCT and nursing practice continues to grow and evolve. As editors, we hope this publication will be a valuable educational resource for nurses caring for patients as they journey through the HSCT continuum.

